NeoImmuneTech announced receipt of IND clearance from the US Federal Drug Administration (FDA) to evaluate NT-I7 (efineptakin alfa), the only clinical-stage long-acting human IL-7, in a Window-of-Opportunity trial for patients with locally recurrent squamous cell carcinoma of head and neck (SCCHN) undergoing salvage surgery.
Pfizer, along with BioNTech, has commenced the phase 2/3 safety and efficacy clinical study to assess a single nucleoside-modified messenger RNA (modRNA) candidate from their BNT162 mRNA-based vaccine programme against SARS-CoV-2.
Inotrem S.A., a biotechnology company specialized in the development of immunotherapies targeting the TREM-1 pathway, announced that it has obtained authorization to launch its phase IIa clinical trial in COVID-19 patients in France, Belgium and the USA.
Medidata, a Dassault Systèmes company, the global leader in creating end-to-end solutions supporting the entire clinical trial process, announced that it is collaborating with Moderna to support clinical trials of mRNA-1273, Moderna’s COVID-19 vaccine candidate.
Clinical-stage pharmaceutical company Humanetics has secured financing from the National Institute of Allergy and Infectious Diseases (NIAID) to carry out a test with its BIO 300 drug in Covid-19 patients.
Expert system services provide peace of mind and ensure that your analyzer is performing optimally to deliver process control.
XyloCor Therapeutics announced it has successfully dosed the first two patients in the EXACT Trial, a Phase 1/2 dose escalation trial evaluating the safety, tolerability and efficacy of its lead candidate XC001 in patients with refractory angina.
AstraZeneca said that the AZD1222 vaccine candidate (formerly ChAdOx1 nCoV-19) licensed from the Oxford University has shown strong immune responses against the SARS-CoV-2 virus in all participants in a phase I/II trial.
ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).
Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.